Dennis E Mayock1, Semsa Gogcu2, Mihai Puia-Dumitrescu3, Dennis W W Shaw4, Jason N Wright4, Bryan A Comstock5, Patrick J Heagerty5, Sandra E Juul3. 1. Division of Neonatology, Department of Pediatrics, University of Washington, Seattle, WA. Electronic address: mayock@uw.edu. 2. Division of Neonatology, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC. 3. Division of Neonatology, Department of Pediatrics, University of Washington, Seattle, WA. 4. Department of Radiology, University of Washington, Seattle, WA. 5. Department of Biostatistics, University of Washington, Seattle, WA.
Abstract
OBJECTIVES: To compare the term equivalent brain magnetic resonance imaging (MRI) findings between erythropoietin (Epo) treated and placebo control groups in infants 240/7-276/7 weeks of gestational age and to assess the associations between MRI findings and neurodevelopmental outcomes at 2 years corrected age. STUDY DESIGN: The association between brain abnormality scores and Bayley Scales of Infant Development, Third Edition at 2 years corrected age was explored in a subset of infants enrolled in the Preterm Erythropoietin Neuroprotection Trial. Potential risk factors for neurodevelopmental outcomes such as treatment assignment, recruitment site, gestational age, inpatient complications, and treatments were examined using generalized estimating equation models. RESULTS: One hundred ten infants were assigned to Epo and 110 to placebo groups. 27% of MRI scans were rated as normal, and 60%, 10%, and 2% were rated as having mild, moderate, or severe abnormality. Brain abnormality scores did not significantly differ between the treatment groups. Factors that increased the risk of higher brain injury scores included intubation; bronchopulmonary dysplasia; retinopathy of prematurity; opioid, benzodiazepine, or antibiotic treatment >7 days; and periventricular leukomalacia or severe intraventricular hemorrhage diagnosed on cranial ultrasound. Increased global brain abnormality and white matter injury scores at term equivalent were associated with reductions in cognitive, motor, and language abilities at 2 years of corrected age. CONCLUSIONS: Evidence of brain injury on brain MRIs obtained at term equivalent correlated with adverse neurodevelopmental outcomes as assessed by the Bayley Scales of Infant and Toddler Development, Third Edition at 2 years corrected age. Early Epo treatment had no effect on the MRI brain injury scores compared with the placebo group.
OBJECTIVES: To compare the term equivalent brain magnetic resonance imaging (MRI) findings between erythropoietin (Epo) treated and placebo control groups in infants 240/7-276/7 weeks of gestational age and to assess the associations between MRI findings and neurodevelopmental outcomes at 2 years corrected age. STUDY DESIGN: The association between brain abnormality scores and Bayley Scales of Infant Development, Third Edition at 2 years corrected age was explored in a subset of infants enrolled in the Preterm Erythropoietin Neuroprotection Trial. Potential risk factors for neurodevelopmental outcomes such as treatment assignment, recruitment site, gestational age, inpatient complications, and treatments were examined using generalized estimating equation models. RESULTS: One hundred ten infants were assigned to Epo and 110 to placebo groups. 27% of MRI scans were rated as normal, and 60%, 10%, and 2% were rated as having mild, moderate, or severe abnormality. Brain abnormality scores did not significantly differ between the treatment groups. Factors that increased the risk of higher brain injury scores included intubation; bronchopulmonary dysplasia; retinopathy of prematurity; opioid, benzodiazepine, or antibiotic treatment >7 days; and periventricular leukomalacia or severe intraventricular hemorrhage diagnosed on cranial ultrasound. Increased global brain abnormality and white matter injury scores at term equivalent were associated with reductions in cognitive, motor, and language abilities at 2 years of corrected age. CONCLUSIONS: Evidence of brain injury on brain MRIs obtained at term equivalent correlated with adverse neurodevelopmental outcomes as assessed by the Bayley Scales of Infant and Toddler Development, Third Edition at 2 years corrected age. Early Epo treatment had no effect on the MRI brain injury scores compared with the placebo group.
Authors: Steven P Miller; Donna M Ferriero; Carol Leonard; Robert Piecuch; David V Glidden; J Colin Partridge; Marta Perez; Pratik Mukherjee; Daniel B Vigneron; A James Barkovich Journal: J Pediatr Date: 2005-11 Impact factor: 4.406
Authors: Miriam Martinez-Biarge; Floris Groenendaal; Karina J Kersbergen; Manon J N L Benders; Francesca Foti; Ingrid C van Haastert; Frances M Cowan; Linda S de Vries Journal: Neonatology Date: 2019-05-20 Impact factor: 4.035
Authors: L T L Sie; A A M Hart; J van Hof; L de Groot; W Lems; H N Lafeber; J Valk; M S van der Knaap Journal: Neuropediatrics Date: 2005-04 Impact factor: 1.947
Authors: Steven P Miller; Camilla Ceppi Cozzio; Ruth B Goldstein; Donna M Ferriero; J Colin Partridge; Daniel B Vigneron; A James Barkovich Journal: AJNR Am J Neuroradiol Date: 2003-09 Impact factor: 3.825
Authors: Jessica Rose; Majid Mirmiran; Erin E Butler; Cindy Y Lin; Patrick D Barnes; Rosanne Kermoian; David K Stevenson Journal: Dev Med Child Neurol Date: 2007-10 Impact factor: 5.449
Authors: Sandra E Juul; Bryan A Comstock; Rajan Wadhawan; Dennis E Mayock; Sherry E Courtney; Tonya Robinson; Kaashif A Ahmad; Ellen Bendel-Stenzel; Mariana Baserga; Edmund F LaGamma; L Corbin Downey; Raghavendra Rao; Nancy Fahim; Andrea Lampland; Ivan D Frantz Iii; Janine Y Khan; Michael Weiss; Maureen M Gilmore; Robin K Ohls; Nishant Srinivasan; Jorge E Perez; Victor McKay; Phuong T Vu; Jean Lowe; Karl Kuban; T Michael O'Shea; Adam L Hartman; Patrick J Heagerty Journal: N Engl J Med Date: 2020-01-16 Impact factor: 91.245
Authors: Leigh E Dyet; Nigel Kennea; Serena J Counsell; Elia F Maalouf; Morenike Ajayi-Obe; Philip J Duggan; Michael Harrison; Joanna M Allsop; Joseph Hajnal; Amy H Herlihy; Bridget Edwards; Sabrina Laroche; Frances M Cowan; Mary A Rutherford; A David Edwards Journal: Pediatrics Date: 2006-08 Impact factor: 7.124
Authors: Margaretha J Brouwer; Karina J Kersbergen; Britt J M van Kooij; Manon J N L Benders; Ingrid C van Haastert; Corine Koopman-Esseboom; Jeffrey J Neil; Linda S de Vries; Hiroyuki Kidokoro; Terrie E Inder; Floris Groenendaal Journal: PLoS One Date: 2017-05-09 Impact factor: 3.240
Authors: S Arulkumaran; N Tusor; A Chew; S Falconer; N Kennea; P Nongena; J V Hajnal; S J Counsell; M A Rutherford; A D Edwards Journal: AJNR Am J Neuroradiol Date: 2020-08 Impact factor: 3.825